Table 2.
Detection of similar epigenetic markers in blood and in matching primary prostate tumours at a fixed range of assay sensitivity
| Markers for category | Gene location | Category | Blood samples | Tissue samples | Total number of common positive markers | Concordance between blood and tissue samples (%) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 3 | Total number of positive markers in blood samples | 1 | 3 | Total number of positive markers in tissue samples | |||||||||||
| Patient | A | B | C | D | E | A | B | C | D | E | ||||||
| Markers | ||||||||||||||||
| 3 vs 1 | BMP6 | PCa.119.37.39 | 1 | 1 | 0 | 1 | 1 | 4 | 1 | 1 | 1 | 0 | 1 | 4 | 3 | 60 |
| ERG | PCa.119.65.67 | 1 | 1 | 1 | 1 | 1 | 5 | 1 | 0 | 1 | 0 | 1 | 3 | 3 | 60 | |
| MSR1 | PCa.119.77.79 | 1 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 1 | 0 | 1 | 2 | 1 | 20 | |
| Common | MUC1 | PCa.119.121.123 | 1 | 1 | 1 | 1 | 0 | 4 | 1 | 1 | 1 | 1 | 1 | 5 | 4 | 80 |
| DAPK1 | PCa.119.165.167 | 1 | 0 | 1 | 1 | 0 | 3 | 0 | 0 | 1 | 0 | 1 | 2 | 1 | 20 | |
| ACAT1 | PCa.119.57.59 | 1 | 1 | 1 | 1 | 1 | 5 | 1 | 1 | 1 | 1 | 1 | 5 | 5 | 100 | |
| 3 vs 2 | HSD3B2 | PCa.119.129.131 | 1 | 1 | 0 | 1 | 1 | 4 | 1 | 1 | 1 | 0 | 1 | 4 | 3 | 60 |
| VEGFC | PCa.119.205.207 | 1 | 1 | 1 | 1 | 1 | 5 | 1 | 1 | 1 | 1 | 1 | 5 | 5 | 100 | |
| APAF1 | PCa.119.49.51 | 1 | 1 | 1 | 1 | 1 | 5 | 0 | 1 | 1 | 1 | 1 | 4 | 4 | 80 | |
When a PCR band of the correct size is detected, it is given a score of 1. When no band is detected, it is given a score of 0
ACAT1: acetyl-CoA acetyltransferase 1; APAF1: apoptotic peptidase activating factor 1; BMP6: bone morphogenetic protein 6; DAPK1: death associated protein kinase 1; ERG: ETS transcription factor ERG; HSD3B2: hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2; MSR1: macrophage scavenger receptor 1; MUC1: mucin 1, cell surface associated; VEGFC: vascular endothelial growth factor C